Targets › PABPC1
1 program from 1 company in 2 trials: 2 Phase 2; Genitourinary, Oncology; next expected readout Sep 2027.
Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability. Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2. (UniProt, P11940)
Open in Phaseline: the race on PABPC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| baotai Liang | Homoharringtonine Translation inhibitor; binds eukaryotic ribosomal 80S subunit to inhibit protein synthesis | PABPC1 | Phase 2 | Prostate Cancer; Prostate CA | Sep 2027 |
Prostate Cancer (1) Prostate CA (1)
small molecule (1)
baotai Liang (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.